Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17888273 | 0.90 | SLC6A15 (0.39) | MAPTPOLBTDP1ABL1RIN1 | |
| SCHEMBL8259131 | 0.88 | SMN1; SMN2 (0.50) | MAPTPOLBTDP1TSHRGAA | |
| SCHEMBL14243068 | 0.85 | MEN1 (0.40) | TSHRGAAALDH1A1MEN1KMT2A | |
| SCHEMBL17888230 | 0.85 | NOTUM (0.39) | MAPTPOLBTDP1ABL1RIN1 | |
| SCHEMBL14242829 | 0.84 | SLC6A15 (0.39) | MAPTTSHRGAAKDM4EALDH1A1 | |
| SCHEMBL14243233 | 0.84 | SLC6A15 (0.36) | MAPTPOLBTDP1ABL1RIN1 | |
| SCHEMBL19226357 | 0.84 | FAAH (0.37) | MAPTPOLBTDP1ABL1RIN1 | |
| SCHEMBL17888221 | 0.84 | MAPT (0.39) | MAPTPOLBTDP1ABL1RIN1 | |
| SCHEMBL6079220 | 0.84 | L3MBTL1 (0.39) | MAPTTSHRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL17243560 | 0.83 | SLC6A15 (0.36) | MAPTPOLBTDP1ABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-11-30 | — | — | US | disclosed |
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-11-30 | — | — | US | disclosed |
| US-9777018-B2 | Compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-9777018-B2 | Compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| EP-2718279-B1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20130045986-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-21 | — | — | US | disclosed |
| US-20130045986-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-21 | — | — | US | disclosed |
| WO-2012170867-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2012-12-13 | — | — | WO | disclosed |
| EP-0822934-B1 | ANTITHROMBOTIC AMIDINOTETRAHYDROPYRIDYLALANINE DERIVATIVES | PFIZER RES & DEV (IE) | 2000-02-09 | — | — | EP | disclosed |
| US-5861393-A | THROMBIN INHIBITORS; VASCULAR, CARDIOVASCULAR, NERVOUS SYSTEM AND BRAIN DISORDERS; ANTIISCHEMIC AND ANTIINFLAMMATORY AGENTS; RESTENOSIS | PFIZER INC. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5798352-A | Antithrombotic amidinotetrahydropyridylalanine derivatives | PFIZER INC. (US) | 1998-08-25 | — | — | US | disclosed |
| US-5750520-A | SELECTIVE THROMBIN INHIBITORS; WOUND HEALING AGENTS | PFIZER INC. (US) | 1998-05-12 | — | — | US | disclosed |
| EP-0728132-B1 | ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES | PFIZER LTD (GB) | 1997-07-16 | — | — | EP | disclosed |
| EP-0728132-A1 | ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES | PFIZER LTD (GB) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995013274-A1 | ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES | PFIZER LIMITED (GB) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | MAPT 2732/4885POLB 2553/4885TDP1 502/4885 |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | MAPT 4011/4885POLB 2260/4885TDP1 1589/4885 |
| US-20130045986-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | GPR119, GPR39, GPBAR1 | MAPT 3977/4885POLB 4671/4885TDP1 4702/4885 |
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | GPR119, GPR39, GPBAR1 | MAPT 3977/4885POLB 4671/4885TDP1 4702/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | MAPT 2732/4885POLB 2553/4885TDP1 502/4885 |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | HRAS, KRAS, TP53 | MAPT 4011/4885POLB 2260/4885TDP1 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.